A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01318421
Recruitment Status : Terminated
First Posted : March 18, 2011
Last Update Posted : December 14, 2015
Information provided by (Responsible Party):
Elan Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: ELND002 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Study Start Date : December 2010
Actual Primary Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ELND002
ELND002 sc injection
Drug: ELND002

Primary Outcome Measures :
  1. To determine the safety and tolerability of ELND002 including the identification of dose-limiting toxicity(ies) (DLT). [ Time Frame: 1 year ]
    Safety and tolerability will be assessed by frequency and severity of AEs.

Secondary Outcome Measures :
  1. To evaluate the PK/PD/BM measurement of ELND002 in patients with MS. [ Time Frame: 1 year ]
    Measurement of drug concentration, alpha 4 receptor saturation, soluble VCAM and MADCAM.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • This study is open only to subjects who have completed the week 12 visit in study ELND002-MS103 while taking their assigned dose of study drug.

Exclusion Criteria:

  • Subject has no new medical contraindications to continue participation in the study.

Responsible Party: Elan Pharmaceuticals Identifier: NCT01318421     History of Changes
Other Study ID Numbers: ELND002-MS153
First Posted: March 18, 2011    Key Record Dates
Last Update Posted: December 14, 2015
Last Verified: December 2015

Keywords provided by Elan Pharmaceuticals:
Relapsing forms of secondary progressive multiple sclerosis (SPMS)or relapsing-remitting multiple sclerosis (RRMS)

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases